What is PT-141?
PT-141 (bremelanotide) is a peptide that acts on melanocortin receptors in the brain and is studied for low sexual desire. Branded bremelanotide is approved for one use: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 is different from an FDA-approved product: it is not FDA-approved.
These articles cover how it works, what the trials found, side effects such as nausea and blood-pressure changes, and who it may not suit. It is prescription-only: a licensed provider reviews every request, and not everyone qualifies.
13 articles on this topic
-
10 Questions to Ask Before PT-141
A PT-141 visit starts with fit and safety. These ten questions clarify the evidence, medical history, side effects, and follow-up plan.
-
Vyleesi Prescribing Information, in Plain English
Vyleesi's label covers one specific form of low desire, a fixed injection dose, and safety limits. Here are its sections in everyday language.
-
Who Discovered PT-141? It Began as a Tanning Drug
PT-141 began as an accident: a University of Arizona tanning peptide caused unexpected erections in its first volunteers. Here is how that clue became bremelanotide, and what happened to its gray-market sibling.
-
PT-141 News Update: September 2026
The Vyleesi label didn't change this quarter. What did: FDA warning letters that named PT-141 sold online, a lab study on how the peptide breaks down, and a warning about its tanning-drug cousin.
-
PT-141 Clinical Trials: What RECONNECT Found
The pivotal studies found modest improvements in desire and distress in a specific group of premenopausal women. They also found a high nausea rate, a sizable placebo response, and clear limits on what the results can tell us about men or compounded PT-141.
-
PT-141 Half-Life Is About 2.7 Hours
The number is short, but it is not a stopwatch for how long someone feels an effect. Here is what the label's timing, clearance range, and safety limits actually mean.
-
PT-141 10mg Vial: What That Number Means
Ten milligrams describes what is in the whole vial. It does not tell you what to draw up, how many uses you have, or how a nasal product compares; those answers come from the prescription and pharmacy label.
-
Kisspeptin vs PT-141: They Work Differently
Kisspeptin and PT-141 both enter libido conversations, but they act on different systems and do not share the same evidence. PT-141 has larger trials and an approved branded product; kisspeptin's human data are smaller and earlier.
-
How to Use PT-141: It's As-Needed, Not Daily
PT-141 is taken before anticipated activity rather than on a daily schedule. Here is what the approved label sets out, what a compounded vial changes, and what the prescriber decides.
-
PT-141 Benefits: What the Human Trials Show
The strongest evidence is specific: studies found higher desire scores and less distress about low desire in premenopausal women with HSDD. Earlier, smaller trials in men measured erectile response, not broad sexual performance.
-
PT-141 for Men: What the Male Studies Show
PT-141 produced measurable erectile responses in early male trials, including studies involving men who reported an inadequate response to sildenafil. The evidence is limited, route-specific, and not the same as an established male indication.
-
PT-141 Dosage: What Trials and the Label Used
PT-141 is studied and labeled as an as-needed medication, not a daily routine. The practical variables are the prescribed amount, timing before anticipated activity, tolerability, and safe spacing between doses.
-
How Does PT-141 Work? Brain, Not Blood Vessels
PT-141 activates melanocortin receptors; two Phase 3 trials in 1,267 premenopausal women measured desire and distress, not brain circuitry, and the Vyleesi label says its mechanism for improving HSDD is unknown.